Medical Necessity Guidelines:
Genetic and Molecular Diagnostic Testing

Effective: January 1, 2023

Prior Authorization Required If REQUIRED, submit supporting clinical documentation pertinent to service request.	**Yes ☒ No ☐**

Applies to:
COMMERCIAL Products
☒ Tufts Health Plan Commercial products; Fax: 617.972.9409
- CareLink℠ – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization

TUFTS HEALTH PUBLIC PLANS Products
☐ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product); Fax:888.415.9055
☐ Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans; Fax: 888.415.9055
☐ Tufts Health RITogether – A Rhode Island Medicaid Plan; Fax: 857.304.6404
☐ Tufts Health Unify* – OneCare Plan (a dual-eligible product); Fax: 857.304.6304
*The MNG applies to Tufts Health Unify members unless a less restrictive LCD or NCD exists.

SENIOR Products
- Tufts Health Plan Senior Care Options (SCO), (a dual-eligible product) – Refer to the Tufts Health Plan SCO Prior Authorization List
- Tufts Medicare Preferred HMO, (a Medicare Advantage product) – Refer to the Tufts Medicare Preferred HMO Prior Authorization and Inpatient Notification List

To obtain InterQual® SmartSheets™:
- **Tufts Health Plan Commercial Plan products:** If you are a registered Tufts Health Plan provider click here to access the Provider website. If you are not a Tufts Health Plan provider please click on the Provider Log-in and follow instructions to register on the Provider website or call Provider Services at 888.884.2404.
- **Tufts Health Public Plans products:** InterQual SmartSheet(s) available as part of the prior authorization process.

Note: While you may not be the provider responsible for obtaining prior authorization, as a condition of payment you will need to make sure that prior authorization has been obtained.

OVERVIEW

Prior authorization is required for genetic and molecular diagnostic testing. Refer to Medical Necessity Guidelines: Noncovered Investigational Services for genetic tests which are considered investigational and therefore not covered.

The Plan uses ChangeHealthcare InterQual Molecular Diagnostics criteria when reviewing prior authorization requests for coverage of most genetic and molecular diagnostic test(s). A completed InterQual SmartSheet must be submitted along with the completed Genetic and Molecular Diagnostics Testing Authorization Request Form and faxed to the appropriate fax number listed above according to Plan. Include all relevant clinical information as applicable.

Refer to the following Medical Necessity Guidelines for genetic testing not included within this guideline:

- Genetic Testing: BRCA-Related Breast and/or Ovarian Cancer Syndrome
- Comprehensive Genomic Profiling with FoundationOne® CDx or FoundationOne® Liquid CDx to Guide Cancer Treatment in Patients with Advanced Cancer
- Genetic Testing: Gene Expression for Cancer of Unknown Primary
- Genetic Testing: Prenatal Diagnosis, Carrier Screening
- Cell-Free DNA Testing for Fetal Trisomy

- Preimplantation Genetic Diagnosis (PGD)
- Human Leukocyte Antigen Genotyping
- Medical Necessity Guidelines: Genetic and Molecular Diagnostic Testing for Tufts Health Direct, Tufts Health Together, Tufts Health RITogether, Tufts Health Unify
- Human Leukocyte Antigen Genotyping for Tufts Health Direct, Tufts Health Together, Tufts Health RITogether, Tufts Health Unify

The following Coverage Guidelines apply to **ALL** prior authorization requests for genetic and molecular diagnostic testing:

CLINICAL COVERAGE CRITERIA

The Plan may authorize coverage for specific genetic testing, for a Member, when the Member meets **ALL** of the following criteria:

- The Member falls within a high-risk group for a particular disease(s) based on personal history, family history, documentation of a genetic mutation, and/or ethnic or ancestry background.
- Patient clinical history, physical examination and conventional diagnostic testing do not result in a definitive diagnosis of suspected disorder, inherited or otherwise.
- The testing method is considered a scientifically proven method for the identification of a genetic disease.
- InterQual coverage criteria, if applicable, for requested genetic/molecular diagnostic test is met.
- Supporting documentation includes a review of current clinical scenario, past relevant testing results and Member's family history.
    - Documentation must indicate how the results of the genetic test will directly alter the medical management of the Member and/or the Member's current pregnancy.
    - Counseling by a medial geneticist board -certified by American Board of Medical Genetics and Genomics (ABMGG) , genetic counselor certified by American Board of Genetic Counseling (ABGC) ABGC **Certified Genetic Counselor** (CGC®) or genetics clinical nurse certified by American Nurses Credentialing Center or Genetics Nursing Credentialing Commission.
    - Genetic and molecular diagnostic testing can be submitted/ordered by a medical geneticist The American College of Medical Genetics and Genomics ("ABMGG"), a member Board of the American Board of Medical Specialties (ABMS), or MD with expertise in treatment of the targeted disease.
    - **Medical necessity letters or genetic testing request forms submitted by the performing lab and signed by the requesting provider will not be accepted as sole documentation.**

PLAN MODIFICATION TO INTERQUAL

Thyroid nodule testing- For the following SmartSheets:

- Afirma Gene Expression Classifier
- ThyroSeq v.3

Section 10: Bethesda III, atypia or follicular lesion of undetermined significance (AUS/FLUS)

Criteria 1.A- Repeat FNA is not required (consider criteria point met

LIMITATIONS

- Testing for the purposes of confirming a suspected diagnosis of a disorder that can be diagnosed based on clinical evaluation alone will not be covered.
- **Genetic tests whose clinical utility is scientifically unproven. Refer to the** Noncovered Investigational Services Medical Necessity Guidelines.
- Genetic testing for Ehlers-Danlos Syndrome (EDS) in Patients with Joint Hypermobility, Skin Hyperextensibility and/or Tissue Fragility [i.e., Arthrochalasia EDS, EDS type VIIA (COL1A1 gene mutation), EDS type VIIB (COL1A2 gene mutation), Classic Type EDS (COL5A1 gene mutation, COL5A2 gene mutation)], including EDS panel testing, is noncovered. Refer to the Noncovered Investigational Services Medical Necessity Guidelines. **NOTE:** Genetic testing for **vascular** EDS (EDS type IV, COL3A 1 mutation) is covered when criteria is met.
- Testing for conditions which cannot be altered by medical management or prevented by specific interventions will not be covered.

- Testing solely for the purpose of informing the management of Member's family member(s) will not be covered.
- Testing must be performed at a contracting laboratory when available.
- A duplicate genetic test for an inherited condition unless there is uncertainty about the validity of the existing test result.[1]
- Testing panels, including but not limited to, multiple genes and/or multiple conditions, should be targeted to testing which is reasonable and medically necessary for therapeutic decision making.

CODES

The following CPT/HCPCS codes require prior authorization:

-

Code	Description
81107	Human platelet Antigen 3 genotyping (HPA-3) ITGA2B integrin, alpha 2b [platelet gyycoprotein IIIb of IIIb/IIIa complex], antigen CD41 [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-3a/b (I843S)
81108	Human Platelet Antigen 4 genotyping (HPA-4) ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT]. Post-transfusion purpura), gene analysis, common variant, HPA-4a/b (R143Q)
81109	Human Platelet Antigen 5 genotyping (HPA-5) ITGA2 (integrin, alpha 2 [CD49B, alpha 2 subunit of VLA-2 receptor] {Gpla)] 9eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant (eg, HPA-5a/b (K505e))
81110	Human Platelet Antigen 6 genotyping (HPA-6w), ITGB3 (integrin , beta 3 [platelet glycoprotein IIIa, antigen CD61] (GPIIIa)) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura) gene analysis, common variant, HPA-6a/b (r489Q)
81111	Human Platelet Antigen 9 genotyping (HPA-9w), ITGA2B (integrin, alph 2b [platelet glycoprotein IIIb of IIIb/IIIa complex, antigen CD41] [GpIIb]) (eg, neonatal alloimmune thromocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-9a/b (V837M)
81112	Human Platelet Antigen 15 genotyping (HPA-15), CD109 (CD109 molecule) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-15a/b (S682Y)
81120	IDH1 (isocitrate dehydrogenase 1 [NADP+], soluable) (eg, glioma), common variants (eg, R132H, R132C)
81121	IDH2 (isocitrate dehydrogenase 2 [NADP+], soluable) (eg, glioma), common variants (eg, R140W, R172M)
81161	DMD (dystrophin) (e.g., Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed
81168	CCND1/IGH (t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed
81170	ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (e.g., acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain
81171	AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
81172	AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)
81173	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence
81174	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant

[1] Choosing Wisely®, an initiative of the American Board of Internal Medicine (AIBM) Foundation. Five things physicians and patients should question. The American College of Medical Genetics and Genomics. July 10, 2015.

Code	Description
81175	ASXL 1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence
81176	ASXL 1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted sequence analysis (eg, exon 12)
81177	ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81178	ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81179	ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81180	ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81181	ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81182	ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81183	ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81184	CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
81185	CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence
81186	CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant
81187	CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81188	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
81189	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence
81190	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)
81191	NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis
81192	NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis
81193	NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis
81194	NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis
81201	APC (adenomatous polyposis coli) (e.g., familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence
81202	APC (adenomatous polyposis coli) (e.g., familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants
81203	APC (adenomatous polyposis coli) (e.g., familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; duplication/deletion variants
81204	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)
81206	*BCR/ABL1 (t(9;22))* (e.g., chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative
81207	*BCR/ABL1 (t(9;22))* (e.g., chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative

Code	Description
81208	*BCR/ABL1 (t(9;22))* (e.g., chronic myelogenous leukemia) translocation analysis; major breakpoint, other breakpoint, qualitative or quantitative
81210	BRAF (V-RAF Murine Sarcoma Viral Oncogene Homolog B1) (e.g., colon cancer, gene analysis, V600E variant)
81218	CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (e.g., acute myeloid leukemia), gene analysis, full gene sequence
81219	CALR (calreticulin) (e.g., myeloproliferative disorders), gene analysis, common variants in exon 9
81224	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; intron 8 poly-T analysis (e.g., male infertility)
81225	CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *4, *8, *17)
81226	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)
81227	CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *5, *6)
81228	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (e.g., Bacterial Artificial Chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)
81229	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities
81233	BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)
81234	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles
81236	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence
81237	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)
81238	F9(coagulation factor IX) (eg, hemophilia B) full gene sequence
81239	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)
81240	F2 (prothrombin, coagulation factor II) (e.g., hereditary hypercoagulability) gene analysis, 20210G>A variant
81241	F5 (coagulation Factor V) (e.g., hereditary hypercoagulability) gene analysis, Leiden variant
81245	FLT3 (fms-related tyrosine kinase 3) (e.g., acute myeloid leukemia), gene analysis, internal tandem duplication (ITD) variants (i.e., exons 14, 15)
81246	FLT3 (fms-related tyrosine kinase 3) (e.g., acute myeloid leukemia), gene analysis; tyrosine kinase domain (TKD) variants (e.g., D835, I836)
81247	G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; common variant(s) (eg, A, A-)
81248	G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant(s)
81249	G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequence
81252	GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence

Code	Description
81253	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1 deletions in GJB2 and GJB6 genes GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; known familial variants GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; known familial variants
81254	GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (eg, nonsyndromic hearing loss) gene analysis, common variants
81256	HFE (hemochromatosis) (e.g., hereditary hemochromatosis) gene analysis, common variants (e.g., C282Y, H63D)
81257	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis, for common deletions or variant (e.g., Southeast Asian, Thai, Filipino, Mediterranean, alpha3.7, alpha4.2, alpha20.5, and Constant Spring)
81258	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, Hbh disease), gene analysis; known familial variant
81259	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, Hbh disease), gene analysis; full gene sequence
81261	IGH@ (Immunoglobulin heavy chain locus) (e.g., leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (e.g., polymerase chain reaction)
81262	IGH@ (Immunoglobulin heavy chain locus) (e.g., leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (e.g., Southern blot)
81263	IGH@ (Immunoglobulin heavy chain locus) (e.g., leukemia and lymphoma, B-cell), variable region somatic mutation analysis
81264	IGK@ (Immunoglobulin kappa light chain locus) (e.g., leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)
81269	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, Hbh disease), gene analysis; duplication/deletion variants
81270	JAK2 (Janus kinase 2) (e.g., myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant
81271	HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
81272	KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (e.g., gastrointestinal stromal tumor [GIST], acute myeloid leukemia, melanoma), gene analysis, targeted sequence analysis (e.g., exons 8, 11, 13, 17, 18)
81273	KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (e.g., mastocytosis), gene analysis, D816 variant(s)
81274	HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)
81275	KRAS(V-KI-RAS2 Kirsten Rat Sarcoma viral oncogene) gene analysis, variants in codons 12 and 13
81276	KRAS (Kirsten rat sarcoma viral oncogene homolog) (e.g., carcinoma) gene analysis; additional variant(s) (e.g., codon 61, codon 146)
81278	IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative
81279	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13)
81283	IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant
81287	MGMT (O-6-methylguanine-DNA methyltransferase) (eg, glioblastoma multiforme), promoter methylation analysis

Code	Description
81288	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; promoter methylation analysis
81292	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis
81293	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants
81294	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants
81295	MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis
81296	MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants
81297	MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants
81298	MSH6 (mutS homolog 6 [E. coli]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis
81299	MSH6 (mutS homolog 6 [E. coli]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants
81300	MSH6 (mutS homolog 6 [E. coli]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants
81301	Microsatellite instability analysis of markers for mismatch repair deficiency, includes comparison of neoplastic and normal tissue
81302	MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; full sequence analysis
81303	MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; known familial variant
81304	MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; duplication/deletion variants
81305	MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant
81307	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence
81308	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant
81309	PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20)
81310	NPM1 (nucleophosmin) (e.g., acute myeloid leukemia) gene analysis, exon 12 variants
81311	NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (e.g., colorectal carcinoma), gene analysis, variants in exon 2 (e.g., codons 12 and 13) and exon 3 (e.g., codon 61)
81314	PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) (e.g., gastrointestinal stromal tumor [GIST]), gene analysis, targeted sequence analysis (e.g., exons 12, 18)
81315	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (e.g., promyelocytic leukemia) translocation analysis; common breakpoints (e.g., intron 3 and intron 6), qualitative or quantitative
81316	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (e.g., promyelocytic leukemia) translocation analysis; single breakpoint (e.g., intron 3, intron 6 or exon 6), qualitative or quantitative

Code	Description
81317	PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis
81318	PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants
81319	PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants
81320	PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)
81321	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis
81322	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant
81323	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant
81324	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis
81325	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis
81326	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant
81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (e.g., Prader-Willi syndrome and/or Angelman syndrome), methylation analysis
81332	SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, Member 1) (e.g., alpha-1-antitrypsin deficiency), gene analysis, common variants (e.g., *S and *Z)
81333	TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)
81334	RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy), gene analysis, targeted sequence analysis (eg, exons 3-8)
81336	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence
81337	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)
81338	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R)
81339	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10
81340	TRB@ (T cell antigen receptor, beta) (e.g., leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (e.g., polymerase chain reaction)
81341	TRB@ (T cell antigen receptor, beta) (e.g., leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (e.g., Southern blot)
81342	TRG@ (T cell antigen receptor, gamma) (e.g., leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)
81343	PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81344	TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles

Code	Description
81345	TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)
81347	SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L)
81348	SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L)
81349	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis
81350	UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (e.g., irinotecan metabolism), gene analysis, common variants (e.g., *28, *36, *37)
81351	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence
81352	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology)
81353	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant
81357	U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P)
81360	ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)
81361	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia beta thalassemia, hemoglobinopathy); common variant(s) (eg, HbS, HbC, HbE)
81362	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia beta thalassemia, hemoglobinopathy); known familial variant(s)
81363	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia beta thalassemia, hemoglobinopathy); duplication/deletion variant(s)
81364	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia beta thalassemia, hemoglobinopathy); full gene sequence
81400	Molecular pathology procedure, Level 1 (e.g., identification of single germline variant [e.g., SNP] by techniques such as restriction enzyme digestion or melt curve analysis)
81401	Molecular pathology procedure, Level 2 (e.g., 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat)
81402	Molecular pathology procedure, Level 3 (e.g., > 10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants 1 exon)
81403	Molecular pathology procedure, Level 4 (e.g., analysis of single exon by DNA sequence analysis, analysis of > 10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)
81404	Molecular pathology procedure, Level 5 (e.g., analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)
81405	Molecular pathology procedure, Level 6 (e.g., analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons)
81406	Molecular pathology procedure, Level 7 (e.g., analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)

Code	Description
81407	Molecular pathology procedure, Level 8 (e.g., analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of > 50 exons, sequence analysis of multiple genes on 1 platform)
81408	Molecular pathology procedure, Level 9 (e.g., analysis of > 50 exons in a single gene by DNA sequence analysis)
81410	Aortic dysfunction or dilation (e.g., Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); genomic sequence analysis panel, must include sequencing of at least 9 genes, including FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, and MYLK
81411	Aortic dysfunction or dilation (e.g., Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); duplication/deletion analysis panel, must include analyses for TGFBR1, TGFBR2, MYH11, and COL3A1
81413	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A
81414	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including KCNH2 and KCNQ1
81430	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); genomic sequence analysis panel, must include sequencing of at least 60 genes, including CDH23, CLRN1, GJB2, GPR98, MTRNR1, MYO7A, MYO15A, PCDH15, OTOF, SLC26A4, TMC1, TMPRSS3, USH1C, USH1G, USH2A, and WFS1
81431	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1 deletions in GJB2 and GJB6 genes
81434	Hereditary retinal disorders (eg, retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes, including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RDH12, RHO, RP1, RP2, RPE65, RPGR, and USH2A
81435	Hereditary colon cancer syndromes (e.g., Lynch syndrome, familial adenomatosis polyposis); genomic sequence analysis panel, must include analysis of at least 7 genes, including APC, CHEK2, MLH1, MSH2, MSH6, MUTYH, and PMS2
81436	Hereditary colon cancer syndromes (e.g., Lynch syndrome, familial adenomatosis polyposis); duplication/deletion gene analysis panel, must include analysis of at least 8 genes, including APC, MLH1, MSH2, MSH6, PMS2, EPCAM, CHEK2, and MUTYH
81437	Hereditary neuroendocrine tumor disorders (e.g., medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must include sequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL
81438	Hereditary neuroendocrine tumor disorders (e.g., medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL
81439	Inherited cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy) genomic sequence analysis panel, must include sequencing of at least 5 genes, including DSG2, MYBPC3, MYH7, PKP2, and TTN

Code	Description
81441	Inherited bone marrow failure syndromes (IBMFS) (eg, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, congenital amegakaryocytic thrombocytopenia) sequence analysis panel, must include sequencing of at least 30 genes, including BRCA2, BRIP1, DKC1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, GATA1, GATA2, MPL, NHP2, NOP10, PALB2, RAD51C, RPL11, RPL35A, RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS, TERT, and TINF2
81443	Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH
81445	Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis
81449	Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis
81450	Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed
81451	Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NOTCH1, NPM1, NRAS), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis
81479	Unlisted molecular pathology procedure
81519	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score (Oncotype DX®, Genomic Health)
81521	Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis (MammaPrint®, Agendia, Inc)
81523	Oncology (breast), mRNA, next-generation sequencing gene expression profiling of 70 content genes and 31 housekeeping genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk to distant metastasis
81541	Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score (Prolaris ®, Myriad Genetic Laboratories, Inc.)
81546	Oncology (thyroid), mRNA, gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious)
81552	Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis

Code	Description
81595	Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score
81599	Unlisted multianalyte assay with algorithmic analysis
86386	Nuclear Matrix Protein 22 (NMP22), qualitative
S3840	DNA analysis for germline mutations of the RET proto-oncogene for susceptibility to multiple endocrine neoplasia type 2
S3841	Genetic testing for retinoblastoma
S3842	Genetic testing for Von Hippel-Lindau disease
S3845	Genetic testing for alpha-thalassemia
S3846	Genetic testing for hemoglobin E beta-thalassemia
S3850	Genetic testing for sickle cell anemia
S3854	Gene expression profiling panel for use in the management of breast cancer treatment
S3861	Genetic testing, sodium channel, voltage-gated, type V, alpha subunit (SCN5A) and variants for suspected Brugada Syndrome
S3865	Comprehensive gene sequence analysis for hypertrophic cardiomyopathy
S3866	Genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (HCM) in an individual with a known HCM mutation in the family (Effective 4/1/09)
S3870	Comparative genomic hybrization (CGH) microarray testing for developmental delay, autism spectrum disorder and/or mental retardation (e.g., SignatureChip®)
0016U	Oncology (hematolymphoid neoplasia), RNA, BCR/ABL1 major and minor breakpoint fusion transcripts, quantitative PCR amplification, blood or bone marrow, report of fusion not detected or detected with quantitation (BCR-ABL1 major and minor breakpoint fusion transcripts, University of Iowa, Department of Pathology, Asuragen)
0017U	Oncology (hematolymphoid neoplasia), JAK2 mutation, DNA, PCR amplification of exons 12-14 and sequence analysis, blood or bone marrow, report of JAK2 mutation not detected or detected (JAK2 Mutation, University of Iowa, Department of Pathology)
0022U	Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapy(ies) to consider (Oncomine™ Dx Target Test, Thermo Fisher Scientific)
0023U	Oncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or non-detection of FLT3 mutation and indication for or against the use of midostaurin (LeukoStrat® CDx FLT3 Mutation Assay, Invivoscribe Technologies, Inc.)
0026U	Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy") (Thyroseq Genomic Classifier, CBLPath, Inc, University of Pittsburgh Medical Center)
0027U	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15 (*JAK2* Exons 12 to 15 Sequencing, Mayo Clinic)
0046U	FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative (FLT3 ITD MRD by NGS, LabPMM LLC, an Invivoscribe Technologies, Inc. Co.)
0049U	NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative (*NPM1* MRD by NGS, LabPMM LLC, an Invivoscribe Technologies, Inc Company)
0069U	Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score (miR-31now™, GoPath Laboratories)

Code	Description
0154U	FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3) (therascreen® *FGFR* RGQ RT-PCR Kit, QIAGEN, QIAGEN GmbH)
0155U	PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y) (therascreen® *PIK3CA* RGQ PCR Kit, QIAGEN, QIAGEN GmbH)
0172U	Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin-embedded tissue, algorithm quantifying tumor genomic instability score (myChoice® CDx, Myriad Genetics Laboratories, Inc, Myriad Genetics Laboratories, Inc)
0177U	Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as PIK3CA gene mutation status (therascreen® *PIK3CA* RGQ PCR Kit, QIAGEN, QIAGEN GmbH)
0230U	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), full sequence analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions
0231U	CACNA1A (calcium voltage-gated channel subunit alpha 1A) (eg, spinocerebellar ataxia), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) gene expansions, mobile element insertions, and variants in non-uniquely mappable regions
0232U	CSTB (cystatin B) (eg, progressive myoclonic epilepsy type 1A, Unverricht-Lundborg disease), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions
0234U	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
0235U	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
0237U	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia), genomic sequence analysis panel including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
0238U	Oncology (Lynch syndrome), genomic DNA sequence analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
0287U	Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high)
0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score

Code	Description
0339U	Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer

REFERENCES

1. Choosing Wisely®, an initiative of the American Board of Internal Medicine (AIBM) Foundation. Five things physicians and patients should question. The American College of Medical Genetics and Genomics. July 10, 2015. Accessed on December 1, 2015 at choosingwisely.org/societies/american-college-of-medical-genetics-and-genomics.
2. Centers for Medicare & Medicaid Services (CMS). Local Coverage Determination (LCD): MolDX: Next-Generation Sequencing for Solid Tumors (L38045). 2021. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38045&ver=14
3. Centers for Medicare & Medicaid Services (CMS). Local Coverage Article: Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer (A54795). 2022 https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=54795&ver=39&

1. Raby BA. Tools for genetics and genomics. Slavotinek A, ed. Up ToDate. Waltham, MA: Up ToDate Inc. http:www.uptodate.com (Accessed on August 13, 2018).
2. Commonwealth of Massachusetts, Department of Public Health. 105 CMR: Department of Public Health.105 CMR 270.000: Blood Screening of Newborns for Treatable Diseases and Disorders. Last accessed September 10, 2019 at mass.gov/files/documents/2017/09/11/105cmr270.pdf?_ga=2.161004157.1131899221.1569946687-818236440.1562067663
3. Genetics Home Reference: Your Guide to Understanding Genetic Conditions.ghr.nlm.nih.gov/primer/testing/genetictestin
4. Ricciuti B, Kravets S, et al. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. Journal for ImmunoTherapy of Cancer. (2019) 7:87. Accessed August 30, 2019 at doi.org/10.1186/s40425-019-0572-6.
5. Duma M, Santana-Davila R, Molia JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. n August 2019;94(8):1623-1640 n Accessed August 30, 2019 at doi.org/10.1016/j.mayocp.2019.01.013 mayoclinicproceedings.org/.
6. Laufer-Geva S, Rozenblum AB, et al. The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer. Journal of Thoracic Oncology. 2018; 13(11):1705–1716.
7. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Next Generation Sequencing (90.2). Medicare Coverage Database. Retrieved on October 21, 2019 at: cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=372&ncdver=1&DocID=90.2&bc=gAAAABAAAAAA&
8. NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 2.2020-September 3, 2019. Accessed on October 22, 2019 at nccn.org/professional.
9. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 1.2020-November 6, 2019. Accessed on October 22, 2019 at nccn.org/professional.
10. American College of Obstetricians and Gynecologists. Carrier screening for genetic conditions. Committee Opinion, Committee of Genetics, Number 691, March 2017. Accessed January 6, 2020.

APPROVAL HISTORY

February 1, 2007: Reviewed by the Clinical Coverage Criteria Committee

Subsequent endorsement date(s) and changes made:

- January 30, 2008: Comparative genomic hybridization through microarray analysis and Preimplantation Genetic Determination limitations were removed from this guideline.
- February 11, 2009: For an April 1, 2009 effective date – new codes added.
- August 5, 2009: For a January 1, 2010 effective date: S3870 added to MNG.
- February 1, 2010: Reviewed by Medical Specialty Policy Advisory Committee (MSPAC), no changes.
- March 2011: Reviewed at MSPAC, no changes.
- January 1, 2012: New CPT codes added.

- March 7, 2012: Reviewed by Integrated Medical Policy Advisory Committee (IMPAC), no changes.
- December 20, 2012: Codes 81161, 81324, 81325, 81326, 81479 added to the Medical Necessity Guideline as requiring Prior Authorization, effective January 1, 2013.
- December 11, 2013: Reviewed by IMPAC, coding updated effective January 1, 2014
- July 25, 2014: Reviewed by IMPAC for effective date of November 1, 2014, added information regarding the use of Interqual®
  Molecular Diagnostics criteria as a reference for the review of all genetic/molecular testing requests.
- August 29, 2014: Additional clarification language related to November 1, 2014 notice. Added codes already requiring review/prior authorization not previously listed (81599, 84999, 81370-81377, 81206-81208).
- September 10, 2014: IMPAC voted to maintain internally developed medical necessity guidelines for BRCA, Cancer of Unknown Primary, Retinoblastoma.
- September 30, 2014: Adopted by Tufts Health Plan – Network Health Commercial Plans and Tufts Health Plan – Network Health Medicaid Plans.
- October 16, 2014: Change to effective date for use of Interqual® Molecular Diagnostics criteria from November 1, 2014 to February 1, 2015.
- November 19, 2014: Reviewed by IMPAC, update to overview section. Links to Noncovered Investigational Services (NCIS) and Genetic Testing Request Form added. Instructions for finding Clinical Evidence Summaries added. Added specification for requests from laboratories. Added disclaimer points regarding code lists: e.g., list may not be all inclusive, deleted codes and codes not effective are not reimbursable. Added 81235, status change from NCIS to requiring Prior Authorization. Added 81287 back to this guideline after resolution of discrepancy with programming status. Added the following codes from Medical Necessity Guidelines to be retired due to change to Interqual® criteria: 81201-81203, 81210, 81241, 81243, 81244, 81275, 81280, 81282, 81292-81300, 81302-81304, 81317-81319, 81331, 83890-83898, 83900-83906, 83912, 84999, 86386, 89290, 89291, S3833, S3834, S3845, S3846, S3854, S3861, S3870. Added codes that do not require prior authorization for reference.
- January 1, 2015: Coding updated per AMA CPT® for effective date 2/1/15. The following codes added: 81246, 81288, 81410, 81411, 81435, 81436, 81519.
- January 22, 2015: Change to effective date for use of Interqual® Molecular Diagnostics criteria from February 1, 2015 to March 2, 2015.
- January 23, 2015: Coding updated per AMA CPT®, 1/1/15 coding changes, for effective date 3/2/15. The following code added: 81420.
- January 26, 2015: Codding updated. CPT codes 81221, 81222, 81223 and 81224 added to list of codes which do not require prior authorization for clarification of CF testing.
- June 10, 2015: Coverage of CPT codes 81321, 81322 and 81323 reviewed by IMPAC. Effective October 1, 2015, status change from non-covered investigational service to prior authorization required.
- August 12, 2015: Reviewed by Integrated Medical Policy Advisory Committee (IMPAC). Effective September 21, 2015 Genetic Testing, Retinoblastoma MNG will be retired. Refer to InterQual® Clinical Evidence Summary, Retinoblastoma. Applicable coding updated.
- September 2015: Branding and template change to distinguish Tufts Health Plan products in "Applies to" section. Added Tufts Health Freedom Plan products, effective January 1, 2016.
- October 14, 2015: Reviewed at IMPAC. Effective April 1, 2016, Afirma Thyroid FNA Analysis to be covered with prior authorization
- December 9, 2015: Reviewed by IMPAC. For effective date April 1, 2016, refer to "Array-based Cytogenetic Testing for Detection of Chromosomal Abnormalities" Clinical Evidence Summary for Genomic Microarray Analysis Testing for Intellectual Disability, Developmental Delay, Multiple Congenital Anomalies, and Autism Spectrum Disorders . For effective date July 1, 2016, clarification of molecular diagnostics and genetic testing will be added. Additional criteria added will require genetic counseling by a board certified genetic counselor or MD geneticist and will allow requests from MD's with expertise in targeted disease. Repeat genetic testing will be added to limitations section. Coding updated per AMA CPT® coding changes and description. Effective 12/9/15 CPT 89290, 89291, S3833 and S3834 removed. Refer to Preimplantation Genetic Determination MNG for CPT 89290 and 89291.

- December 31, 2015: Coding updated. Per AMA CPT®, effective December 31, 2015 the following code(s) deleted: S3854; and effective January 1, 2016 the following code(s) added: 81170, 81218, 81219, 81272, 81273, 81276, 81311, 81314, 81412, 81437, 81438
- February 11, 2016: Afirma Thyroid FNA Analysis (CPT 81545) covered with prior authorization
- March 9, 2016: Reviewed by IMPAC: Additional criteria added for effective date of 7/1/16 will require that patient history, physical examination and conventional diagnostic testing do not result in a definitive diagnosis of suspected disorder. Limitation of genetic testing panels added for effective date of 7/1/16. Effective 7/1/16, myRisk® Hereditary Cancer test will be covered with prior authorization. Effective 7/1/16 CPT 81235 will be covered without prior authorization.
- July 1, 2016: Coding updated. S3854 re-instated.
- October 28, 2016: Coding table added to clarify accepted CPT code(s) for myRISK™ Hereditary Cancer Test and myRISK™ Update Test, prior authorization request.
- December 14, 2016: Reviewed by IMPAC, renewed without changes.
- December 14, 2016: ThyroSeq® Next Generation Sequencing reviewed by IMPAC. Effective January 10, 2017, ThyroSeq® (CPT 81479) is covered with prior authorization.
- December 31, 2016: Coding updated. Per AMA CPT®, effective December 31, 2016 the following code(s) deleted: 81280, 81281, 81282 and effective January 1, 2017 the following code(s) added: 81413, 81414, 81439.
- April 12, 2017: Reviewed by IMPAC. Addition to limitation section, genetic tests whose clinical utility is scientifically unproven with added link to Noncovered Investigational Services MNG. Language change (scientifically added) to coincide with change to EOC language. Links added to Genetic Testing: Maternal Tests for Fetal Trisomy MNG and Genetic Testing: Prenatal, Preconception MNG.
- April 2017: Added RITogether Plan product to template. For MNGs applicable to RITogether, effective date is August 1, 2017.
- August 1, 2017: For effective date August 1, 2017, Interqual SmartSheets to be submitted with Genetic and Molecular Diagnostics Testing Authorization Request Form. Coding updated. The following ICD-10-CM and HCPCS codes are added: 0016U, 0017U, S3850.
- October 1, 2017: Coding updated. For effective date October 1, 2017, the following ICD-10-CM codes are added: 0022U, 0023U.
- December 13, 2017: Reviewed by IMPAC, renewed without changes. CPT 81434 will be covered with prior authorization.
- December 31, 2017: Coding updated. Per AMA CPT®, effective January 1, 2018 the following code(s) added: 81107. 81108, 81109, 81110, 81111, 81112, 81120, 81121, 81175, 81176, 81238, 81247, 81248, 81249, 81258, 81259, 81269, 81283, 81334, 81361, 81362, 81363, 81364, 81521, 81541, 0026U, 0027U.
- January 16, 2018: CPT 81434 added to list of CPT/HCPCS codes requiring prior authorization.
- May 31, 2018: Code description updated.
- June 26, 2018: Coding updated. Per AMA CPT®, effective July 1, 2018 the following code(s) added: 0046U, 0049U.
- September 12, 2018: Reviewed By IMPAC. Clarification to criteria when genetic test will directly alter the treatment and/or medical management of a condition which has been clinically diagnosed. Link to Prenatal, Preconception MNG added to limitations section.
- October 1, 2018: Coding updated. Per AMA CPT®, effective October 1, 2018 the following code(s) added: 0069U.
- October 2018: Template and disclaimer updated
- December 3, 2018: 2018.2 Interqual upgrade for Tufts Health Commercial products including Tufts Health Freedom Plan. Effective December 17, 2018, Interqual upgrade is effective for Tufts Health Direct and Tufts Health Together. Effective January 14, 2019, Interqual upgrade effective for Tufts Health RITogether.
- December 31, 2018: Coding updated. Per AMA CPT®, effective January 1, 2019 the following code(s) added: 81171, 81172, 81173, 81174, 81177, 81178, 81179, 81180, 81181, 81182, 81183, 81184, 81185, 81186, 81187, 81188, 81189, 81190, 81204, 81233, 81234, 81236, 81237, 81239, 81271, 81274, 81305, 81320, 81333, 81343, 81344, 81345.
- April 25, 2019: Effective April 25, 2019, 2018 Interqual upgrade includes Interqual smartsheets Thyroid Nodule Genetic Testing : Afirma MTC Classifier and Thyroid Nodule Genetic Testing: Multi-gene panel for thyroid nodule
- July 17, 2019: Reviewed at IMPAC. THP modification to Interqual thyroid nodule testing criteria added. A repeat FNA of thyroid nodule is not required when initial FNA cytology result indicates

Bethesda IV, suspicious for follicular or Hürthle cell neoplasm (SFN/SHCN) or follicular neoplasm (FN)

- September 18, 2019: Reviewed at IMPAC. Effective January 1, 2020, CPT 81443 requires prior authorization.
- November 20, 2019: Reviewed by IMPAC. For effective date November 20, 2019, CPT 81445 added and may be covered with prior authorization for NSCLC diagnosis. CPT 81450 added and may be covered with prior authorization for AML diagnosis. For effective date April 1, 2020, CPT 81337 will require prior authorization. For effective date April 1, 2020, CPT 81337 will require prior authorization.
- January 1, 2020: Coding updated. Per AMA CPT®, effective January 1, 2020 the following code(s) added: 81307, 81308, 81309, 0154U, 0155U
- January 6, 2020: Coverage of CPT 81337, SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)) reviewed by IMPAC voting committee. CPT 81337 will remain covered and will not require prior authorization effective April 1, 2020. For clarification, CPT 81329, 81336 and 81337 added to MNG under genetic testing covered without prior authorization.
- February 19, 2020: Reviewed at IMPAC. THP Modification to InterQual criteria for thyroid nodule testing added: Section 10: Bethesda III, atypia or follicular lesion of undetermined significance (AUS/FLUS) Criteria 1.A- Repeat FNA is not required (consider criteria point met)
- July 1, 2020: Coding updated. Per AMA CPT®, effective July 1, 2020 the following code(s) added:0172U, 0177U.
- July 9, 2020, Fax number for Unify updated.
- July 29, 2020: Reference to Medical Necessity Guidelines: BRCA-Related Breast and/or Ovarian Cancer Syndrome removed from CPT 0172U.
- September 16, 2020: Reviewed by IMPAC, renewed without changes.
- December 31, 2020: Coding updated. Per AMA CPT®, effective December 31, 2020 the following code(s) deleted: 81545 and effective January 1, 2021 the following code(s) added: 81168, 81191, 81192, 81193, 81194, 81278, 81279, 81338, 81339, 81347, 81348, 81351, 81352, 81353, 81357, 81360, 0230U, 0231U, 0232U, 0234U, 0235U, 0237U, 0238U.
- April 21, 2021: CPT 81546 Oncology (thyroid), mRNA reviewed by IMPAC and added with prior authorization required; effective date of May 15, 2021.
- July 21, 2021:Reviewed at IMPAC. For effective date July 21, 2021, CPT 81552 and 81595 are covered with prior authorization.
- August 18, 2021: Reviewed by IMPAC, renewed without changes
- January 1, 2022: Coding updated. Per AMA CPT®, effective January 1, 2022 the following code(s) added: 81349, 81523, 0287U, 0288U.
- February 17, 2022: Freedom removed from template
- April 20, 2022: Reviewed by Medical Policy Approval Committee (MPAC). Addition of codes 81252, 81253, 81254, 81430 and 81431 to MNG requiring PA effective June 1, 2022.
- March 16, 2022: Reviewed by MPAC. Effective July 1, 2022, myRISK™ Hereditary Cancer Test is non-covered, considered investigational.
- July 20, 2022: Reviewed by MPAC. For effective date September 1, 2022, FoundationOne CDx, CPT 0037U, is covered with prior authorization. InterQual 2022 updates. Language clarification regarding coverage of testing for EDS. Effective October 1, 2022, Medical Necessity Guideline is no longer applicable to Tufts Health Together, Tufts Health Direct, Tufts Health Unify and Tufts Health RITogether. AIM Specialty Health® (AIM) will oversee medical necessity review for Tufts Health Public Plans. For effective date November 1, 2022, prior authorization is required for all prenatal testing. CPT codes 81224, 81336, 81337 require prior authorization and are added. CPT code table of tests covered without prior authorization removed, CPT 81243, 81244 and language applicable to prenatal testing removed-refer to Prenatal Diagnosis, Carrier Screening MNG and Cell-Free DNA Testing for Trisomy MNG.
- October 1, 2022: Coding updated. Per AMA CPT®, effective October 1, 2022 the following code(s) added: 0339U.
- October 19, 2022: Reviewed at MPAC. Removal of HLA genotyping CPT codes, addition of links to HLA genotyping MNGs.
- November 16, 2022: Reviewed at MPAC. Effective 1/1/23, refer to MNG: Comprehensive Genomic Profiling with FoundationOne CDx™ or FoundationOne Liquid CDx to Guide Cancer Treatment in Patients with Advanced Cancer for clinical coverage criteria applicable to CPT

0037U and 0239U. Unlisted 84999 removed. Coding updated: Per AMA CPT®, effective January 1, 2023 the following code(s) added: 81441, 81449, 81451.

BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION

Medical Necessity Guidelines are developed to determine coverage for benefits, and are published to provide a better understanding of the basis upon which coverage decisions are made. We make coverage decisions using these guidelines, along with the Member's benefit document, and in coordination with the Member's physician(s) on a case-by-case basis considering the individual Member's health care needs.

Medical Necessity Guidelines are developed for selected therapeutic or diagnostic services found to be safe and proven effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in our service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. We revise and update Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of Members. The use of this guideline is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to eligibility and benefits on the date of service, coordination of benefits, referral/authorization, utilization management guidelines when applicable, and adherence to plan policies, plan procedures, and claims editing logic.